Shansong Zheng - 1Qilu Pharmaceutical Co., Ltd

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 16 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

First-in-human Study to Evaluate the Safety, Tolerability, and Population Pharmacokinetic/pharmacodynamic Target Attainment Analysis of FL058 Alone and in Combination with Meropenem in Healthy Subjects

Zhiwei Huang,Xinyi Yang,Yi Jin,Jicheng Yu,Guoying Cao,Jingjing Wang,Yingying Hu, Jingyi Dai,Jufang Wu,Qiong Wei, Yan Tian,Shuyan Yu, Xu Zhu,Xiaomeng Mao,Wei Liu, Hong Liang,Shansong Zheng, Yunfei Ju, Zenghua Wang,Jing Zhang,Xiaojie Wu

ANTIMICROBIAL AGENTS AND CHEMOTHERAPYno. 1 (2024)

引用0浏览0WOS引用

In Vitro Pharmacokinetics/pharmacodynamics of FL058 (a Novel Beta-Lactamase Inhibitor) Combined with Meropenem Against Carbapenemase-Producing Enterobacterales

Zhiwei Huang,Xingchen Bian,Yi Li,Jiali Hu,Beining Guo,Xinyi Yang, Yi Jin,Shansong Zheng,Xinmei Wang, Cong Gao,Jing Zhang,Xiaojie Wu

FRONTIERS IN PHARMACOLOGY（2024）

引用0浏览0WOS引用

Pharmacokinetics, metabolism, excretion and safety of iruplinalkib (WX-0593), a novel ALK inhibitor, in healthy subjects: a phase I human radiolabeled mass balance study

Yicong Bian,Sheng Ma, Qingqing Yao, Tao Hu,Mingjing Ge, Hongting Li,Shansong Zheng,Zheming Gu, Hao Feng,Zhenwen Yu,Chenrong Huang,Hua Zhang,Limei Zhao,Liyan Miao

EXPERT OPINION ON INVESTIGATIONAL DRUGS（2024）

引用0浏览0WOS引用

Iruplinalkib (WX‑0593), a Novel ALK/ROS1 Inhibitor, Overcomes Crizotinib Resistance in Preclinical Models for Non-Small Cell Lung Cancer

Yingying Yang,Qingmei Zheng,Xinmei Wang,Shuyong Zhao, Wenshu Huang,Linchao Jia,Cuicui Ma, Shicong Liu, Yongpeng Zhang, Qianqian Xin, Yan Sun,Shansong Zheng

Investigational new drugs（2023）

引用4浏览0WOS引用

Abstract 5457: QLH11811, a Selective 4Th-Generation EGFR Inhibitor for Osimertinib-Resistant EGFR-mutant NSCLC

Shansong Zheng, Wei Deng,Qingmei Zheng,Yingying Yang, Na Li, Tan Pang, Xueying Feng,Simon Taylor, Lina Ma, Yaqiong Wu, Ziwei Zhao

Cancer researchno. 12_Supplement (2022): 5457-5457

引用0浏览0引用

QLH11811, a selective 4^th-generation EGFR inhibitor for osimertinib-resistant EGFR-mutant NSCLC

Shansong Zheng, Wei Deng,Qingmei Zheng,Yingying Yang, Na Li, Tan Pang, Xueying Feng,Simon Taylor, Lina Ma, Yaqiong Wu, Ziwei Zhao

CANCER RESEARCHno. 12 (2022)

引用0浏览0引用

WX-0593 Combined with an Epithelial Growth Factor Receptor (EGFR) Monoclonal Antibody in the Treatment of Xenograft Tumors Carrying Triple EGFR Mutations

Qingmei Zheng, Dongmei Chen,Xinmei Wang,Yingying Yang,Shuyong Zhao,Xin Dong,Cuicui Ma,Xin Zhang,Huicheng Duan, Yan Sun,Shansong Zheng

Annals of Translational Medicine（2022）

引用2浏览0WOS引用

Pharmacodynamics of WX-0593 combined with bevacizumab biosimilar on human lung cancer xenograft mouse models

Shansong Zheng,Qingmei Zheng,Xin Dong,Xinmei Wang, Dongmei Chen,Huicheng Duan,Cuicui Ma,Chenwei Zhang

CANCER RESEARCH（2022）

引用0浏览0引用

Abstract 5459: Synergistic Effects of WX-0593 in Combination with Panitumumab on Osimertinib-Resistant EGFR-mutantnon-small Cell Lung Cancer in Vitro and in Vivo

Shansong Zheng,Qingmei Zheng, Dongmei Chen,Xinmei Wang,Xin Dong,Xin Zhang,Cuicui Ma,Huicheng Duan,Chenwei Zhang

Cancer researchno. 12_Supplement (2022): 5459-5459

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn